Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cybin Inc.
< Previous
1
2
3
4
5
6
7
Next >
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
December 10, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
December 04, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
November 18, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
November 14, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
November 13, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
October 31, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
October 24, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
October 03, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
October 01, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
September 24, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Provides Corporate Update on Upcoming Clinical Milestones
September 19, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Completion of Previously Announced Share Consolidation
September 19, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
August 27, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
August 13, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
August 08, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
June 26, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 19, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
June 11, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
May 29, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
May 14, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
May 06, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate at the 27th Annual Milken Institute Global Conference
April 25, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
April 18, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
April 16, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 10, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
March 18, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
March 15, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
March 14, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.